Cargando…
Developing and paying for medicines for orphan indications in oncology: utilitarian regulation vs equitable care?
Despite ‘orphan drug’ legislation, bringing new medicines for rare diseases to market and securing funding for their provision is sometimes both costly and problematic, even in the case of medicines for very rare ‘ultra orphan’ oncological indications. In this paper difficulties surrounding the intr...
Autores principales: | Davies, J E, Neidle, S, Taylor, D G |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3251875/ https://www.ncbi.nlm.nih.gov/pubmed/22215105 http://dx.doi.org/10.1038/bjc.2011.544 |
Ejemplares similares
-
Reply: Comment on ‘Developing and paying for medicines for orphan indications in oncology: utilitarian regulation vs equitable care?’
por: Davies, J E, et al.
Publicado: (2012) -
Comment on: ‘Developing and paying for medicines for orphan indications in oncology: utilitarian regulation vs equitable care?’
por: Bielack, S S
Publicado: (2012) -
Utilitarian vs deontological ethics in medicine and dentistry
por: Dillon, Jasjit
Publicado: (2021) -
Expanding indications for liver transplantation in the era of liver transplant oncology
por: Panayotova, Guergana, et al.
Publicado: (2021) -
Utilitarian and deontological ethics in medicine
por: Mandal, Jharna, et al.
Publicado: (2016)